Abstract 31P
Background
Cervical cancer is a major public health concern as it is the fourth leading cause of cancer-related fatalities among women. India has the highest incidence of cervical cancer worldwide. Omics diagnostic tools, particularly proteomics, are helpful in tracking the development of the disease as cancer therapy continues to shift towards precision medicine. The primary objective of this study was to explore the global protein expression patterns of cervical cancer in the Indian population for the first time to encourage the application of current diagnostic and treatment modalities.
Methods
We employed MS-based quantitative global (Label-free quantification or LFQ) and targeted proteomics (multiple reaction monitoring or MRM) in bio-banked tissue samples of cervical cancer and healthy tissue (Control=8, Tumor=7; 6 Paired, 2 unpaired). With a very small amount of starting tissue material (10-12 mg) proteomic biomarker profiling was conducted as pilot research. Finally, a complex set of protein candidates belonging to the mRNA splicing and MTORC1 signaling pathway has been confirmed and refined at the peptide level by MRM assay.
Results
We observed proteins belonging to the mRNA processing and maturation via alternative splicing pathway were overexpressed in cervical tumors. Heterogeneous nuclear ribonucleoproteins (hnRNPs), the components of spliceosome complex regulate both constitutive and alternative splicing in tumors. We found at least 5 hnRNPs and few HSP (heat-shock proteins) to be significantly overexpressed in tumors via global proteomics. Validation of candidate hnRNPs (HNRNPA2, HNRNPA1) and Heat-shock proteins (HSPs) were done by targeted proteomics. Furthermore, we developed a comprehensive panel of peptides which can be investigated to check for the effectiveness of tumour development which pave the way towards a better diagnosis.
Conclusions
This foundation study, for the very first time, facilitated the development of a panel of proteomic biomarkers of Cervical cancer in Indian population. We propose that a set of these markers including HNRNPs can be further useful for the development of a complete biomarker panel for cervical cancer diagnosis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Indian Institute of Technology, Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract